Kornimate/medical-research-clean huggingface dataset:
exploring water-free sodium storage

Conditions: Peritoneal Dialysis, Heart Failure

Summary: the overarching goal of this proposal is to definitively establish if acute water free na storage and release occurs, if the amount stored/released is of a quantity that is physiologically relevant, and if the location is intracellular vs. extracellular.

this study is designed as a an ultra-rigorous inpatient balance study. the main purpose of the study is to determine if significant mobilizable non- extracellular volume (ecv) na storage occurs in humans. this is a randomized, blinded crossover study. patients will be randomized to na free 5% dextrose solution or 1.5% standard peritoneal dialysis (pd) fluid (dianeal 1.5% low calcium pd solution with standard 132 mmol/l na and osmolarity of 344 mosmol/l) and will receive treatment for 5 days, following a 6 week wash out patient will return to undergo 5 days of alternate therapy.

Eligibility criteria:
inclusion criteria: * esrd patients actively undergoing pd with a reliably functioning pd catheter * systolic blood pressure \> 130 mmhg * serum sodium \>135 mmol/l * daily urine output \< 400ml * stable pd prescription for at least 2 months without requirement of 4.25% glucose pd solution * pd vintage of at least 6 months * euvolemic as defined by the patient at their dry weight and free of any signs or symptoms of volume overload, per referring nephrologist exclusion criteria: * poorly controlled diabetes with hemoglobin a1c\>9% * 1 or more episodes of peritonitis in the previous 6 months or active infection of the peritoneal dialysis catheter * anemia with hemoglobin \<8g/dl * inability to give written informed consent or follow study protocol. * urinary incontinence * body weight \< 60kg * gastrointestinal disease that causes diarrhea or expectation of sodium losses in stool. * use of amiodarone in the last 6 months (which will interfere with tissue iodine ascertainment).
cardiac function as measured by non-invasive electrical velocimetry cardiac monitor in hospitalized children

Conditions: Cardiac Output; Blood Pressure

Summary: to assess whether a non-invasive cardiac output monitor can follow heart function in children during treatments in the hospital. to establish a normal reference for children who are well and awake.

the aim of the study is to evaluate the ability of a new fda-approved non-invasive electrical velocimetry (ev) cardiac monitor called aesculon (cardiotronic inc, la jolla ca) to detect and trend hemodynamic changes in hospitalized ambulatory pediatric patients during recovery from acute illness. we postulate that if the cardiac monitor can trend hemodynamic changes in hypertensive patients whose mean arterial pressure (map) decreases to normal levels, or hypotensive patients whose map increases to normal levels over several days, it may improve our understanding of different disease processes and allow us to improve care. we also seek to establish normative data for different measures provided by the aesculon monitor - specifically cardiac output (co) and systemic vascular resistance (svr), which are the prime determinants of map.

Eligibility criteria:
inclusion criteria: * medical patients without complex medical history with expected hospital stay for less than 10 days * uncomplicated medical patients as define as (1) previously healthy children or (2) children with diagnosis of a single chronic medical disorder that is not associated with cardiac dysfunction exclusion criteria: * congenital heart disease with and without repair (includes pfo, asd and pda, cardiac valve disease or pulmonary hypertension * chronic lung disease (except asthma) * abnormal hemoglobin (ssd)

Keywords: non-invasive cardiac output monitor electrical velocimetry aesculon icon pediatrics normal reference
hemodynamic effects of dexmedetomidine in septic shock

Conditions: Septic Shock

Summary: the current treatment regimen of patients with septic shock requires a sufficient hemodynamic support aiming to preserve tissue oxygen requirements and perfusion. therefore, aggressive fluid challenge and vasopressor agents play a pivotal role. to increase total peripheral resistance and preserve organ perfusion, a continuous infusion of catecholamines is often needed. because sepsis is usually associated with adrenergic receptor and post-receptor abnormalities, the efficacy of such treatment regimens often gradually decreases over time, thereby complicating hemodynamic support. experimental evidence suggest that α-2 agonists increase pressor responsiveness following lipopolysaccharide administration. this study will assess the effects of the sedation with dexmedetomidine (α-2 agonist) on norepinephrine requirements in patients with septic shock.

the present study was designed as a prospective study. all patients enrolled in the study will require norepinephrine to maintain map between 65 and 75 mmhg despite adequate volume resuscitation and will be sedated according to istitutional guidelines with propofol and remifentanyl. after 8 h had elapsed during stable hemodynamic conditions, an initial set of measurements will be obtained during the sedation with propofol and remifentanyl. this set of measurements will be considered as baseline. in the patients in which conventional sedation will be replaced by dexmedetomidine and remifentanyl, a second set of measurements will be obtained after 4 h had elapsed during stable conditions. a final set of mesurements will be obtained after another 8-h period in stable conditions after switcheing back again to propofol and remifentanyl, . during the observational period the dosage rate of norepinephrine will be adjusted to maintain the same threshold map of 65-75 mmhg all other medications were held constant.

Eligibility criteria:
inclusion criteria: * septic shock * need for sedation exclusion criteria: -
keratinocyte growth factor to prevent autoimmunity after alemtuzumab treatment of multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to test a novel strategy to prevent the clinical problem of secondary autoimmunity following alemtuzumab treatment of multiple sclerosis. the hypothesis is that autoimmunity after alemtuzumab can be prevented by giving a drug that promotes thymic t cell regeneration (palifermin, kepivance®).

this is a single-centre, double-blinded, randomised controlled trial of palifermin (kepivance) vs. placebo in the prevention of autoimmunity following alemtuzumab treatment of multiple sclerosis. the dose of palifermin (kepivance)used in this trial will be informed by a dose-escalation study.

Eligibility criteria:
inclusion criteria: * male or non-pregnant, non-lactating female patients * \> 18 years of age, and \<50 years of age inclusive * diagnosis of ms using mcdonald's 2010 criteria, including mri abnormalities consistent with mcdonald's 2010 criteria. * onset of first ms symptoms within 10 years on the date the icf is signed * edss score 0.0 to 5.0 (inclusive) at screening * at least 2 clinical episodes of ms in the 2 years prior to study entry, with at least 1 attack within 12 months, which may have occurred whilst on disease-modifying therapy, namely any beta interferon or glatiramer acetate. * serum il-7≤7pg/ml exclusion criteria: * any progressive form of multiple sclerosis * previous thymectomy * previous treatment with alemtuzumab, natalizumab, mitoxantrone, cyclophosphomide, cladribine, rituximab or any other immunosuppressant or cytotoxic therapy (other than steroids and disease-modifying therapies listed above) * history of malignancy * personal history of clinically significant autoimmune disease, other than multiple sclerosis (including but not limited to: thyroid disease, immune cytopenias, inflammatory bowel disease, diabetes, lupus, severe asthma) * intolerance of pulsed corticosteroids, especially a history of steroid psychosis * major systemic disease or other illness that would, in the opinion of the investigator, compromise patient safety or interfere with the interpretation of study results. * seropositivity for human immunodeficiency virus (hiv) * past or present hepatitis b infection (positive hepatitis b serology) * pregnant women or male and female patients who do not agree to use effective contraception during the study. * medical, psychiatric, cognitive or other conditions that, in the investigator's opinion, compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study.

Keywords: alemtuzumab palifermin reconstitution thymus
clinical characteristics of lip hemangiomas

Conditions: Hemangioma

Summary: lip hemangiomas are at higher risk than those located in other sites. however, studies about clinical characteristics of lip hemangiomas have not been enough. the investigators want to conduct a prospective study on the clinical features of lip hemangiomas.

hemangiomas involving lip are of special concern, since they occur in a prominent location on the face and can distort lip anatomy and lead to disfunction. infantile hemangiomas in lip had significantly higher incidence than the others. it is often difficult to decide which patient with an lip hemangioma is at higher risk. the investigators are interested in conducting a study on the clinical features of lip hemangiomas. the investigators are collecting medical records and photos of lip hemangiomas, including demographic information, maternal process, birth, location, size and complication. based on the data, sum up the main points of clinical characteristics and complication.

Eligibility criteria:
inclusion criteria: * only lip hemangiomas visiting between june 1, 2010 and october 1, 2014 were included in this study, which was defined as any infantile hemangioma covering any part of vermilion. exclusion criteria: * perioral hemangiomas which did not involve vermilion were excluded.
protein expression in samples from young patients with rhabdomyosarcoma

Conditions: Sarcoma

Summary: rationale: studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors find better ways to treat cancer. purpose: this research trial studies protein expression in samples from young patients with rhabdomyosarcoma.

objectives: * to measure the protein expression of candidate proteins in human rhabdomyosarcoma (rms) tumor samples. outline: archived tumor tissue samples are analyzed for protein expression (i.e., notch1, hey1, fgfr4, and sp1) by ihc techniques and standard commercially available antibodies. candidate proteins are then correlated with each patient age, gender, rhabdomyosarcoma (rms) tumor stage, and rms tumor subtype.

Eligibility criteria:
disease characteristics: * tumor tissue samples from children with rhabdomyosarcoma (rms) enrolled in the children's oncology group clinical trials * alveolar rhabdomyosarcoma (arms) * embryonal rhabdomyosarcoma (erms) patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: alveolar childhood rhabdomyosarcoma previously treated childhood rhabdomyosarcoma previously untreated childhood rhabdomyosarcoma recurrent childhood rhabdomyosarcoma embryonal childhood rhabdomyosarcoma
prevalence of malnutrition and frailty among the urban community elderly in bandung

Conditions: Frail Elderly

Summary: the goal of this observational study is to learn prevalence of malnutrition and frailty in elderly in community in bandung. the main question it aims to answer: what is the prevalence of malnutrition and frailty in elderly in bandung community?

the increase in the number and proportion of the elderly population poses various challenges, especially in the health sector. the elderly tend to be more vulnerable to health problems, such as malnutrition and frailty. data on the prevalence of malnutrition and frailty in the elderly can be used as a basis for taking preventive and treatment measures for both conditions. this study aims to determine the prevalence of malnutrition and frailty in the elderly in the bandung city community. descriptive research with a cross-sectional approach was conducted on 71 elderly participants in the bandung city community. the sampling method used was consecutive sampling. the study used the mini nutritional assessment-short form (mna-sf) questionnaire to assess malnutrition and the kihon checklist (kcl) to assess frailty.

Eligibility criteria:
inclusion criteria: * age above 60 years old * domicile in bandung city * able to mobilize without assistive devices * able to see and read * willing to participate in the study exclusion criteria: * history of hospitalization within the previous month * mini mental status examination ( mmse ) score \< 24

Keywords: frail elderly malnutrition community
a long-term safety study of s5g4t-1 in the treatment of papulopustular rosacea

Conditions: Papulopustular Rosacea

Summary: to assess the safety of s5g4t-1 when applied once daily for up to 40 weeks in participants with papulopustular rosacea who completed either study sgt-54-01 (nct03448939) or study sgt-54-02 (nct03564119).

this is a long-term safety study for participants who completed either study sgt-54-01 or sgt-54-02. participants will be admitted into the study only after a written informed consent has been obtained and not missing more than 1 visit of visits 3, 4 or 5 in these studies. eligible participants for enrollment will apply the study product, s5g4t-1, daily for up to an additional 40 weeks for a total of up to 52 weeks for some participants.

Eligibility criteria:
inclusion criteria: 1. participants must sign an institutional review board (irb) approved written informed consent for the extension study. 2. participants must complete 12 weeks or within the week 12 window time (± 4 days) of the double-blind treatment period of study sgt-54-01 or study sgt-54-02 and missed not more than 1 visit of visits 3, 4 or 5 in study sgt-54-01 or study sgt-54-02. exclusion criteria: -
evaluation of pulmonary doppler signals in patients with systemic sclerosis(ssc)

Conditions: Systemic Sclerosis; Pulmonary Hypertension

Summary: doppler signals can be recorded from the lung parenchyma by means of a pulsed doppler ultrasound system incorporating a special signal processing package- the transthoracic parametric doppler (tpd) (echosense ltd., haifa, israel). systemic sclerosis patients often develop pulmonary vascular disease leading to pulmonary hypertension. the tpd system may provide important insight into pulmonary blood vessels characteristics by the lds (lung doppler signals) signals that are related to pulmonary hypertension. the tpd performance in detecting pah in ssc patients will be assessed in the study.


Eligibility criteria:
inclusion criteria: 1. able and willing to give signed informed consent prior to enrollment 2. male or female, ≥ 18 years of age 3. diagnosis of ssc according to 2013 acr/eular ssc classification criteria (van den hoogen 2013): score ≥ 9. 4. patients with rhc data available from measurement within 3 weeks prior to tpd assessment 5. no change in or initiation of pah specific therapy between the last rhc and tpd exclusion criteria: 1. people unable or unwilling to give informed consent. 2. pcwp or lvedp \> 15 mmhg 3. any ph etiology outside group 1 (dana point, 2008) 4. pregnant women 5. patients having severe chest wall deformity

Keywords: systemic sclerosis pulmonary hypertension lung doppler signals
risk factors for bowel dysfunction at preschool and early childhood age in children with hirschsprung disease

Conditions: Bowel Dysfunction; Hirschsprung Disease; Risk Factor; Incontinence; Constipation

Summary: bowel dysfunction has been proven as the most common complication after pull-through(pt) of hirschsprung disease(hd) ，which may persist to adulthood and lead to social problems.the reason of bowel dysfunction is complicated and the risk factors were not defined.

hirschsprung disease (hd) is a distinctive congenital disease with the absence of ganglion cells in the distal intestine leads to distal bowel obstruction and defecation disorders. hd is a rare disease, with a reported incidence of 1:5,000, requiring proper surgical treatment for the maintenance of normal or near-normal bowel movement.to date, there is insufficient evidence to recommend a preferred or superior method for the surgical repair, and a pull-through with or without laparoscopy was the most common procedure for correction of hd,which may have faster recovery and less rate of complication compared to other surgical approaches.the short or long-term outcomes of hd have been deeply assessed in the past few years,and bowel dysfunction,consist of soling, incontinence and constipation, had been proven as the most common complication,which may be a ongoing issue and lead to social problems,which should not be ignored. otherwise,there were many reports proved that poor bowel function in preschool and early childhood may lead to social problems and depression in adolescence or adult.many factors may lead to bowel dysfunction in hd, including length of aganglionic segement,anastomotic leakage or redo-pt,unsuitable timing of surgery,etc.thus,the present study was designed to seek the risk factors for bowel dysfunction of hd,which is meaningful to maintain or improve the bowel function in preschool and early childhood.

Eligibility criteria:
inclusion criteria: 1. clinical dignosis with hirschsprung disease 2. completed the toilet training exclusion criteria: 1. redo-pull-through, 2. down syndrome or other co-morbidities that impaired functional outcomes

Keywords: hirschsprung disease bowel function associated factors
immunogenicity and safety of covid-19 vaccine in people living with hiv

Conditions: People Living With HIV; COVID-19; Vaccine

Summary: severe acute respiratory syndrome coronavirus 2 (sars-cov-2) has caused pandemic since outbreak in 2020. patients with hiv may be at higher risk than those without hiv for coronavirus disease 2019 (covid-19). at present, limited data are available on the safety and immunogenicity of coronavirus vaccine for patients with hiv.

this study is a prospective, single-arm, open-label clinical trial. a total of 200 patients with hiv infection were included in this vaccination study. all of the patients will further accept 12 months follow-up study after vaccination. safety and immunogenicity will be carefully recorded and detected.

Eligibility criteria:
inclusion criteria: 1. age above 18 years and less than 60 years 2. patients diagnosed as hiv infection with viral inhibition or preparing to start antivirus therapy were included . 3. the functions of multi-organs were normal or basically normal, and there are no contraindications for vaccination. exclusion criteria: 1. patients with acute attack of chronic diseases. 2. patients have history of convulsion, epilepsy, encephalopathy and psychosis. 3. patients who are allergic to any component of the vaccine, or have a serious history of vaccine allergy. 4. pregnant or lactating women. 5. suffering serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, and severe hypertension can not be well controlled by drugs. 6. patients have severe chronic diseases or diseases can not be controlled well during the progress, such as asthma, diabetes, thyroid disease, etc. congenital or acquired angioedema / uroedema. 7. patients who are receiving immunosuppressants such as glucocorticoid.
the use of a quality of life questionnaire in patients with lung cancer

Conditions: Lung Cancer

Summary: this study will investigate the effectiveness of using the european organisation for research and treatment of cancer core quality of life questionnaire (eortc qlq-c30 + lc 13) to identify and target therapies in patients with lung cancer. the study will assess whether using the questionnaire will result in an improvement in qol.

patients with lung cancer who have completed a course of treatment (or who are in-between treatment) at the royal marsden hospital would be eligible for inclusion in the study. participants will be randomised into 3 groups. group 1 - this group will complete the qol questionnaire and will receive targeted therapies by a doctor (and other members of the oncology team) during a clinic consultation. group 2 - will complete the qol questionnaire however the questionnaire will not be seen by the doctor during a clinic consultation. group 3 - the control group will not complete the qol questionnaire before a clinic consultation. all patients will complete a diary of all contact they have with health care professionals during the study. the study will last for 6 weeks and at the end of the study all patients will complete the qol questionnaire.

Eligibility criteria:
inclusion criteria: * male or female age \> 18 years * patients who are able to adequately understand written and spoken english * diagnosis of lung cancer (non small cell, small cell, mesothelioma) * no plan to commence treatment (chemotheraphy, targeted therapies, radioterhapy, surgery) with 6 weeks * both radically or palliatively treated patients remain eligible * patients whose toxicities from their primary treatment has resolved or have stabilised for a period of 7 days exclusion criteria: * patients are taking part on any other qol studies * taking part in any other studies that requires qol questionnaires, extra visits or investigations * currently on treatment (chemotherapy, radiotherapy, surgery or targeted therapies) * they have on going toxicities from their treatment which have not been stablised (required intervention within last 7 days)

Keywords: lung cancer quality of life
is insulin resistance and/or glucose intolerance pathogenetic in the development of a reduced incretin effect

Conditions: Insulin Resistance; Glucose Intolerance

Summary: the purpose of this study is to examine whether there is a causal relationship between insulin resistance and/or glucose intolerance in the development of a defect incretin effect.

in this study we are going to examine the incretin effect before and after the development of insulin resistance and/or glucose intolerance. the incretin effect is the increased insulin response seen after an oral as apposed to an intravenous glucose challenge with identical plasma glucose profiles. this insulin enhancing effect is greatly reduced in type 2 diabetes. since the development of type 2 diabetes is preceded by insulin resistance and glucose intolerance we wanted to examine the incretin effect in the early stages of type 2 diabetes. to do this, we want to induce insulin resistance and/or glucose intolerance. this is achieved by 5 days of treatment with dexamethasone. the incretin effect in this study will be examined by 3 investigations prior to the treatment and 3 days following the treatment. day 1: oral glucose challenge with 75 g of glucose. the subject is asked to drink 75g of glucose suspended in 300ml of water. during the 4 hours of the test, we draw blood at various times during the study to determine the concentration of: glucose, glp-1, gip, glucagon, insulin and c-peptide. day 2: intravenous glucose we duplicate the glucose curve obtained from day 1. we also draw blood during this test to the same end as in day 1. day 3: mixed meal. the subjects are served a mixed meal. during this 4 hour test, we draw blood to examine the response to a standardized meal. the test involves sampling blood as described for the other days.

Eligibility criteria:
inclusion criteria: * caucasians \>20 years * normal glucose tolerance as assessed by the who criteria * first degree relative and at least 1 second degree relative with type 2 diabetes * normal haemoglobin * informed consent exclusion criteria: * liver disease (alat/asat \> 2 times normal value) * kidney disease (s-creatinin \> 130um and/or albuminuria) * heart disease (nyha ii, iii or iv) * treatment with medicine that cannot be paused * pregnancy of breast feeding

Keywords: incretin effect type 2 diabetes glp-1 gip dexamethasone